Joan Puig de Dou – CEO, Kymos Pharma, Spain

Joan Puig de Dou, CEO of Kymos Pharma, a Spanish analytical CRO, shares his insights in the changing dynamics of the industry and explains how remaining independent in the face of industry consolidation is a strategic priority to leverage both quality and specialization for the company’s clients.  
When[biosimilars] come to Europe, they must be tested to meet EU standards. This is an area in which are now focusing on to help biosimilar players enter the European market
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report